FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

[FierceBiotech @FierceBiotech]

Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. https://t.co/THXbl1svOW

[FierceBiotech @FierceBiotech]

Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate that Takeda bet big on last year https://t.co/sDyxWf0aCq

[FierceBiotech @FierceBiotech]

In the race to turn CAR-T cell therapies against autoimmune diseases, Cabaletta Bio has always been blazing its own trail. https://t.co/REb4zJBOOy

[FierceBiotech @FierceBiotech]

As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too https://t.co/OYfDPOy494

[FierceBiotech @FierceBiotech]

As Akeso takes center stage at ASCO, China biotech industry cements its coming of age https://t.co/eAHqfPi1Ca

[FierceBiotech @FierceBiotech]

Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study https://t.co/yxaJUX6eBu

[FierceBiotech @FierceBiotech]

Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases https://t.co/XLqOe5R3kO

[FierceBiotech @FierceBiotech]

To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts https://t.co/ZJkQKCYEsM #ASCO26

[FierceBiotech @FierceBiotech]

Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. https://t.co/MrF8yUC5A7

[FierceBiotech @FierceBiotech]

Cardiff posts updated colorectal cancer data ahead of pivotal push https://t.co/sQ99jmSRLh #ASCO26

[FierceBiotech @FierceBiotech]

With Innovent Biologics garnering buzz in the dealmaking space, Takeda is adding more credence to its own multi-billion-biobucks collab with the Chinese company that granted access to a first-in-class bispecific with “tremendous potential.” https://t.co/ohDtnHS58R #ASCO26

[FierceBiotech @FierceBiotech]

Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas https://t.co/ChVOS4PO76

[FierceBiotech @FierceBiotech]

GSK shared early data suggesting its KIT inhibitor from IDRx could overtake Gleevec as the standard of care for gastrointestinal stromal tumors. https://t.co/B0S8hvzKe8 #ASCO26

[FierceBiotech @FierceBiotech]

Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo https://t.co/OjLLVN3ATu

[FierceBiotech @FierceBiotech]

Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study https://t.co/5bbWCXnRmz

[FierceBiotech @FierceBiotech]

ASCO, Ryght AI team up for breast cancer trial site selection https://t.co/ftkZIrb7KP

[FierceBiotech @FierceBiotech]

Revolution Medicines confident in RAS leadership as rivals square up https://t.co/s6yE3XOBpg

[FierceBiotech @FierceBiotech]

Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% https://t.co/gaqy6S76pT

[FierceBiotech @FierceBiotech]

Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome https://t.co/avN9xy6HAt

[FierceBiotech @FierceBiotech]

Kelonia Therapeutics has shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech. https://t.co/6y09ypAQaP